{"id":908615,"date":"2025-11-11T18:52:11","date_gmt":"2025-11-11T23:52:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"},"modified":"2025-11-11T18:52:11","modified_gmt":"2025-11-11T23:52:11","slug":"telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","title":{"rendered":"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX"},"content":{"rendered":"

<\/p>\n

Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX<\/b><\/p>\n

LOS ANGELES–(BUSINESS WIRE<\/a>)–The DJS Law Group<\/a> reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX<\/a>) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.<\/p>\n

\nShareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n

CLASS PERIOD:<\/b> February 21, 2025 to August 28, 2025<\/p>\n

DEADLINE: <\/b>January 9, 2026<\/p>\n

CASE DETAILS: <\/b>According to the Complaint, the Company made false and misleading statements to the market. Telix overstated its progress in developing and commercializing prostate cancer treatments. The Company also overstated the strength of its supply chain. Based on these facts, Telix\u2019s public statements were false and materially misleading throughout the class period.<\/p>\n

\nIf you are a shareholder who suffered a loss, contact us to participate<\/a>.<\/p>\n

NEXT STEPS FOR SHAREHOLDERS<\/b>: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.<\/p>\n

WHY DJS LAW GROUP?<\/b> DJS Law Group\u2019s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic\/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.<\/p>\n

Join the case<\/a> to recover your losses.<\/p>\n

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251111649754\/en\/<\/a><\/span><\/p>\n

\nDavid J. Schwartz
\n
DJS Law Group
\n
274 White Plains Road, Suite 1
\n
Eastchester, NY 10709
\n
Phone: 914-206-9742
\n
Email: David@djslawllp.com<\/a><\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: February 21, 2025 to August 28, 2025 DEADLINE: January 9, 2026 CASE DETAILS: According to the … <\/p>\n

Continue reading “Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-908615","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTelix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: February 21, 2025 to August 28, 2025 DEADLINE: January 9, 2026 CASE DETAILS: According to the … Continue reading "Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T23:52:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX\",\"datePublished\":\"2025-11-11T23:52:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\",\"name\":\"Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-11-11T23:52:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","og_locale":"en_US","og_type":"article","og_title":"Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk","og_description":"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX LOS ANGELES–(BUSINESS WIRE)–The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (\u201cTelix\u201d or \u201cthe Company\u201d) (NASDAQ: TLX) for violations of \u00a7\u00a710(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: February 21, 2025 to August 28, 2025 DEADLINE: January 9, 2026 CASE DETAILS: According to the … Continue reading \"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-11T23:52:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX","datePublished":"2025-11-11T23:52:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/","name":"Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights \u2013 TLX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-11-11T23:52:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251111649754r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/telix-pharmaceuticals-limited-sued-for-securities-law-violations-contact-the-djs-law-group-to-discuss-your-rights-tlx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Telix Pharmaceuticals Limited Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights \u2013 TLX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=908615"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/908615\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=908615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=908615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=908615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}